Medicine and Dentistry
Androgen Deprivation Therapy
23%
Awareness
7%
Biochemical Recurrence
23%
Biodistribution
23%
Biological Marker
69%
Bladder Cancer
50%
Body Mass Index
23%
Cancer Diagnosis
5%
Cancer Epidemiology
5%
Cancer Prognosis
23%
Cancer Registry
23%
Carcinogenesis
7%
Circulating Tumor DNA
23%
Clinical Significance
23%
Colonoscopy
23%
Conjugate
21%
Consultation
7%
Cross Sectional Study
23%
Cystectomy
25%
Cytoreductive Surgery
23%
Decision Making
36%
Diagnosis
28%
Diagnostic Accuracy
7%
Diagnostic Performance
23%
Dietary Supplement
11%
Disease Course
7%
Diseases
11%
DNA Determination
5%
Enfortumab Vedotin
23%
Gallium 68
100%
Germinoma
23%
Hazard Ratio
7%
Hospital Management
23%
Hydronephrosis
11%
Kidney Stone
23%
Logistic Regression Analysis
9%
Lymph Node
5%
Lymph Node Metastasis
46%
Lymphocyte
46%
Magnetic Resonance Imaging
11%
Malignant Neoplasm
6%
Meta-Analysis
23%
Metastatic Carcinoma
33%
Morphology
23%
Muscle Invasive Bladder Cancer
11%
Neoplasm
15%
Nephrostomy
17%
Neutrophil
46%
Non Muscle Invasive Bladder Cancer
76%
Obstruction
5%
Overall Survival
5%
Patient Counseling
7%
Patient Selection
23%
Percutaneous Nephrolithotomy
11%
Personalized Medicine
7%
PET-MRI
7%
Physical Activity
7%
Polyethylene Terephthalate
46%
Polyp
11%
Positron Emission Tomography
73%
Positron Emission Tomography-Computed Tomography
5%
Prevalence
7%
Progression Free Survival
10%
Proportional Hazards Model
6%
Prostate Cancer
76%
Prostate Specific Membrane Antigen
69%
Prostatectomy
24%
Radiation Therapy
7%
Randomized Controlled Trial
7%
Recurrent Disease
24%
Risk Stratification
15%
Salivary Gland
6%
Seasonal Variation
23%
Seminoma
6%
Side Effect
5%
Systematic Review
23%
Systemic Therapy
23%
Therapeutic Management
7%
Therapy Planning
7%
Transitional Cell Carcinoma
10%
Tumor Diagnosis
9%
Ureter Stone
23%
Urinary Diversion
11%
Urolithiasis
23%
Urology
34%
Urothelial Cancer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Antigen
23%
Biochemical Recurrence
23%
Biodistribution
23%
Biological Marker
49%
Cancer Prognosis
23%
Circulating Tumor DNA
23%
Cross-Sectional Study
23%
Dietary Supplement
11%
Enfortumab Vedotin
23%
Gallium 68
79%
Kidney Stone
23%
Lutetium 177
23%
Lymph Node Metastasis
23%
Lymphocyte Antigen Receptor
23%
Malignant Neoplasm
6%
Neoplasm
30%
Nephrolithiasis
23%
Non Muscle Invasive Bladder Cancer
46%
Obstruction
5%
Polyethylene Terephthalate
92%
Prostate Cancer
76%
Prostate Specific Membrane Antigen
46%
Radioligand
23%
Recurrent Disease
7%
Tracer
23%
Ureter Stone
23%